Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Perseus Proteomics, Inc. ( (JP:4882) ) has issued an announcement.
Perseus Proteomics has secured a JPY 100 million grant under Japan’s FY2026 Drug Discovery Support Promotion Program managed by AMED to advance its antibody candidate PPMX-T003 for aggressive NK-cell leukemia. The funding will support an investigator-initiated clinical trial targeting a rare, rapidly progressing leukemia that predominantly affects younger and middle-aged patients and currently lacks effective treatments.
PPMX-T003 is designed to bind transferrin receptor 1, which is highly expressed in hematopoietic and many cancer cells, with the aim of blocking iron uptake and suppressing malignant cell proliferation. The grant, expected to be provided over up to three fiscal years starting in FY2025 and booked as long-term deposits in the year ending March 2027, offers non-dilutive financing that advances Perseus Proteomics’ clinical development without materially affecting current-year financial results.
The most recent analyst rating on (JP:4882) stock is a Hold with a Yen241.00 price target. To see the full list of analyst forecasts on Perseus Proteomics, Inc. stock, see the JP:4882 Stock Forecast page.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc. is a Japan-based biotech company listed on the TSE Growth market that focuses on drug discovery, particularly antibody-based therapeutics. Its pipeline includes PPMX-T003, a therapy targeting transferrin receptor 1 to disrupt iron uptake in cancer and hematopoietic cells, aiming at difficult-to-treat hematologic malignancies.
Average Trading Volume: 993,449
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.79B
Learn more about 4882 stock on TipRanks’ Stock Analysis page.